An updated cost-effectiveness analysis of pazopanib versus sunitinib as first-line treatment for locally advanced or metastatic renal cell carcinoma in Italy-Reference-Cited by-同舟云学术

An updated cost-effectiveness analysis of pazopanib versus sunitinib as first-line treatment for locally advanced or metastatic renal cell carcinoma in Italy

Published:2020-11-05 Issue:12 Volume:23 Page:1579-1587
ISSN:1369-6998
Container-title:Journal of Medical Economics
language:en
Short-container-title:Journal of Medical Economics

Author:

Capri Stefano¹,Porta Camillo²,Condorelli Claudia³,Premoli Eleonora³,Khare Ankur⁴,Kalra Manik⁴,Modi Niraj⁴,Ratto Barbara⁵

Affiliation:

1. School of Economics and Management, University Cattaneo-LIUC, Castellanza, Italy

2. Chair of Oncology, University of Bari ‘A. Moro’, Bari, Italy

3. Novartis Oncology Italy, Origgio, Italy

4. Novartis Healthcare Pvt. Ltd., Hyderabad, India

5. Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA

Funder

Novartis Pharmaceutical Corporation, East Hanover, NJ, USA.

Publisher

Informa UK Limited

Subject

Health Policy

Link

https://www.tandfonline.com/doi/pdf/10.1080/13696998.2020.1839240

Reference43 articles.

1. GENETIC SYNDROMES ASSOCIATED WITH RENAL CELL CARCINOMA - A REVIEW

2. The Epidemiology of Renal Cell Carcinoma

3. Epidemiology and risk factors for kidney cancer

4. Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies

5. Blood Pressure and Risk of Renal Cell Carcinoma in the European Prospective Investigation into Cancer and Nutrition

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Scoping review of economic analyses of rare kidney diseases;Kidney International Reports;2024-09

2. Sensitivity Analysis in Economic Evaluations of Immuno-Oncology Drugs: A Systematic Literature Review;Value in Health Regional Issues;2023-09

3. Cost-Effectiveness of the First Line Treatment Options For Metastatic Renal Cell Carcinoma in India;JCO Global Oncology;2023-02

4. Out of Date or Best Before? A Commentary on the Relevance of Economic Evaluations Over Time;PharmacoEconomics;2021-12-06

5. Pazopanib or Sunitinib? cost-utility analysis of pazopanib versus sunitinib in the first-line treatment of metastatic renal cell carcinoma in Jordan;Journal of Pharmaceutical Health Services Research;2021-11-01